Tehran University of Medical Sciences Archives of Anesthesiology and Critical Care 2423-5849 3 2 2017 04 23 304 307 EN Abbasali Dehghani Department of Anesthesiology and Intensive Care Medicine, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran Hassan Mohammadi Poor Anvari Department of Anesthesiology and Intensive Care Medicine, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran 2017 02 04 2017 04 17 Background: Post Anesthesia Shivering (PAS) is one of the common complications throughout recovery from general and regional anesthesia. The incidence of this complication is reported to be 40-70% among patients. PAS occurrence depends on various factors such as age, gender and drugs used in anesthesia and surgery time. Granisetron is a serotonin 5HT3 receptor antagonist. Beneficial effects of such drugs have been shown in a limited number of studies. In this study, preventive effects of granisetron in prevention of shivering, nausea and vomiting following spinal anesthesia were evaluated in patients undergoing lower abdominal surgery. Methods: One hundred and five patients aged 18-60 years and with ASA class I or II who were scheduled to undergo elective lower abdominal surgery under spinal anesthesia were studied in 3 groups of 35 patients. After spinal anesthesia, group L received low dose granisetron with a dose of 10μg/kg, group H received high dose granisetron with a dose of 40 μg/kg and group C received normal saline as placebo. After leaving the operating room, patients were monitored in terms of shivering occurrence, time and severity of it and incidence of nausea and vomiting. Results: Incidence of shivering, nausea and vomiting was significantly lower in group H than C. (P=0.009 and 0.008, respectively). However, there was no significant difference between L and C or L and H groups in terms of shivering, or nausea and vomiting occurrence. No side effects of granisetron were observed in the study. Conclusion: High dose granisetron with dose of 40μg/kg significantly reduced the prevalence and severity of PAS and PONV in comparison to placebo. https://aacc.tums.ac.ir/index.php/aacc/article/view/109 https://aacc.tums.ac.ir/index.php/aacc/article/download/109/267